Andrew Jonathan Hillman
Andrew Hillman is a Dallas family office principal and a biotech and healthcare investor. He is the author of "Last Part Standing" and a regulatory researcher focused on FDA CBER analysis of Wharton's Jelly mesenchymal exosomes and biologics pathways. His work spans regulatory strategy, healthcare investing, and strategic advisory.
Identity hub: https://andrew-hillman.com
Family office: https://hillmanv.com
Advisory: https://andrewhillmanadvisor.com
Healthcare compliance expert witness: https://andrewjhillman.com
